Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.
about
Bispecific digoxigenin-binding antibodies for targeted payload deliveryCompounds from the marine sponge Cribrochalina vasculum offer a way to target IGF-1R mediated signaling in tumor cellsModern Technologies for Creating Synthetic Antibodies for Clinical application.A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptorSingle variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies.Engineering of stable bispecific antibodies targeting IL-17A and IL-23.Next generation of antibody therapy for cancer.A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approachRecombinant approaches to IgG-like bispecific antibodies.Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradationMolecular biology of epidermal growth factor receptor inhibition for cancer therapy.Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment.Biological agents versus chemotherapy in the treatment of colorectal cancer.Monoclonal antibody-based therapeutics for leukemia.Inhibiting kinases in malignant gliomas.Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignanciesTargeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives.XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancerInteraction of antibodies with ErbB receptor extracellular regions.Targeting the EGF receptor ectodomain in the context of cancer.Bispecific antibodies for cancer therapy.Research and development of next generation of antibody-based therapeuticsDual targeting strategies with bispecific antibodies.Necitumumab for non-small cell lung cancer.The current status of immunotherapy in peritoneal carcinomatosis.Recent progress in protein-protein interaction study for EGFR-targeted therapeutics.A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation.Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.Precise mapping of an IGF-I-binding site on the IGF-1R.Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.The making of bispecific antibodiesNew magic bullets can hit more than one target.The potential for cancer combination therapy with multi-targeted, single-protein pharmaceuticals.Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.
P2860
Q27667652-D6D683DF-4A44-4BBE-ADDB-828A4E975885Q28468664-E70C9894-15A1-4546-90D1-79E3E027BA2DQ30467308-DCC45393-4909-4B4E-8773-B2BF2AB09164Q30992402-6DAF4033-DC06-4CE6-9C0C-042F66639F91Q33234057-76A194DC-2445-4843-8A61-27972F523EC0Q33519833-474A9D10-E324-4348-A438-8DFB3FBF0328Q33579636-4CE61306-B23A-4C1C-8885-5F67542E51C4Q33846405-A1D8B5CA-0AEA-4115-825E-470E994E7A42Q33925323-72AB193C-4610-4D1E-BA8C-497DC45FBC34Q36139512-F089D0BA-CC7B-4315-AC93-6F9EFDEA308EQ36185627-353C78B4-B9EA-447A-AE0F-D4555DEC610AQ36216092-3FBFF1CB-3E61-4C95-8E10-4059B139457AQ36481002-59D36A98-0322-4EEC-B4F8-8EFEF2876E4DQ36499234-38FFB57F-ED5D-4FE5-BF19-3A430829AA78Q36521850-FA0E5E8A-F36C-4203-90FD-80CFC734FDB7Q36739759-D0B8529E-4B57-4A35-A50B-ED9024D3CA69Q36764876-9D8AC780-4879-449D-8E53-B89C791DD6FCQ36812355-7A8E1D47-E28F-4517-BD0C-530B331C3D3CQ36920799-B68D0F56-E42B-44AD-9933-3EAFE68ABB51Q37138970-9E38E7A6-EF0F-4D72-82C2-01BF6A6C9D41Q37320814-E8FDE5EB-2AE6-4E99-9FDF-ECE8EAF2D4B7Q37600910-DB45034A-859D-48C2-A158-C03FD15575CDQ37773263-0D4A1CFC-AEB9-46FB-B66B-C33E939C1157Q37778732-77BBCE0C-3FB1-43B2-847F-896ADE26689FQ37997559-FA6C0570-8615-4849-9698-EB70BCC0B6BBQ38519582-9EAE9F71-5A43-4EE1-8753-29538182B21EQ38830852-F31C4133-B80A-4E95-86EF-255897B22F94Q38899428-30F3F871-1C10-4351-8D2A-170D87A31E8BQ39133025-89007FB9-2845-4628-B99A-605737954EF3Q39557682-1DCBA6A3-847F-4CDD-A3F3-15E8DEF0D906Q39971767-CA393908-4D79-4778-981A-14A0979C8E25Q40103814-B5ED77EA-63F0-4E01-B95E-25EE120026F4Q40230735-AD773937-AF6A-414C-BAA5-C3B08A96ED53Q40287051-4C62780B-BF17-4921-A9E0-7F339CDAF771Q40448458-040C22CE-E487-4AB3-8576-1288329B9E81Q42323236-D2BC4E10-FF8D-4FE4-9D25-93C108FA3FF5Q47424609-B4F89064-816A-45BA-91FD-91506A992928Q47952691-4AEEAE21-3FCB-4492-AF90-57024C26CA47Q52957112-DBF173F2-1CEF-4B82-B681-849C8FFD1933
P2860
Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Simultaneous blockade of both ...... combinant bispecific antibody.
@ast
Simultaneous blockade of both ...... combinant bispecific antibody.
@en
type
label
Simultaneous blockade of both ...... combinant bispecific antibody.
@ast
Simultaneous blockade of both ...... combinant bispecific antibody.
@en
prefLabel
Simultaneous blockade of both ...... combinant bispecific antibody.
@ast
Simultaneous blockade of both ...... combinant bispecific antibody.
@en
P2093
P2860
P356
P1476
Simultaneous blockade of both ...... ecombinant bispecific antibody
@en
P2093
Anita Persaud
Dale Ludwig
Douglas Burtrum
Haifan Zhang
Larry Witte
Paul Balderes
Peter Bohlen
Xenia Jimenez
Zhenping Zhu
P2860
P304
P356
10.1074/JBC.M310132200
P407
P50
P577
2003-10-23T00:00:00Z